Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Treasury Shares (2016 - 2019)

Celldex Therapeutics has reported Treasury Shares over the past 9 years, most recently at $1110.0 for Q4 2019.

  • Quarterly results put Treasury Shares at $1110.0 for Q4 2019, down 68.75% from a year ago — trailing twelve months through Dec 2019 was $1110.0 (down 68.75% YoY), and the annual figure for FY2019 was $1110.0, down 68.75%.
  • Treasury Shares for Q4 2019 was $1110.0 at Celldex Therapeutics, down from $3552.0 in the prior quarter.
  • Over the last five years, Treasury Shares for CLDX hit a ceiling of $50000.0 in Q4 2016 and a floor of $1110.0 in Q4 2019.
  • Median Treasury Shares over the past 5 years was $6445.0 (2017), compared with a mean of $16121.4.
  • Biggest five-year swings in Treasury Shares: skyrocketed 178.57% in 2015 and later tumbled 87.11% in 2017.
  • Celldex Therapeutics' Treasury Shares stood at $19500.0 in 2015, then soared by 156.41% to $50000.0 in 2016, then tumbled by 87.11% to $6445.0 in 2017, then tumbled by 44.89% to $3552.0 in 2018, then tumbled by 68.75% to $1110.0 in 2019.
  • The last three reported values for Treasury Shares were $1110.0 (Q4 2019), $3552.0 (Q4 2018), and $6445.0 (Q4 2017) per Business Quant data.